Johnson & Johnson announces new data presented at EAN of IMAAVY

Johnson & Johnson announced new data from an indirect treatment comparison that showed consistent and sustained disease control with IMAAVY versus other approved FcRn blockers in adults with generalized myasthenia gravis. These data, featured at the European Academy of Neurology, EAN, 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson & Johnson is presenting. Based on the ITC, which included the pivotal Phase 3 Vivacity-MG3 study data, IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADL scores versus the published Phase 3 data of other marketed FcRn blockers at several timepoints up to 24 weeks of treatment. Results were consistent across multiple ITC methods. Population-adjusted ITCs without a common control exhibited significantly greater mean improvements in MG-ADL scores favoring IMAAVY over other FcRn blockers, at Weeks 8-24 versus one comparator and at Weeks 10-14 versus another comparator. In placebo-adjusted ITCs, IMAAVY was associated with numerically greater efficacy versus one treatment comparator at Weeks 8 and 18-24 and versus another at Weeks 10-14e, with statistical significance at Weeks 10 and 12.